Cytokine and Chemokine Profile Changes in Patients After Intravitreal Conbercept Injection for Diabetic Macular Edema

References

• Klein R, Klein BE, Moss SE. Visual impairment in diabetes. Ophthalmology. 1984;91(1):1–9. doi:10.1016/S0161-6420(84)34337-8
   PubMed Web of Science ®Google Scholar
• Klein R, Klein BE, Moss SE, Cruickshanks KJ. The wisconsin epidemiologic study of diabetic retinopathy. XV. The long-term incidence of macular edema. Ophthalmology. 1995;102(1):7–16. doi:10.1016/S0161-6420(95)31052-47831044
   PubMed Web of Science ®Google Scholar
• Bandello F, Cunha-Vaz J, Chong NV, et al. New approaches for the treatment of diabetic macular oedema: recommendations by an expert panel. Eye (Lond). 2012;26(4):485–493. doi:10.1038/eye.2011.33722241014
   PubMed Web of Science ®Google Scholar
• Do DV, Schmidt-Erfurth U, Gonzalez VH, et al. The DA VINCI Study: Phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema. Ophthalmology. 2011;118(9):1819–1826. doi:10.1016/j.ophtha.2011.02.01821546089
   PubMed Web of Science ®Google Scholar
• Schmidt-Erfurth U, Lang GE, Holz FG, et al. Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension study. Ophthalmology. 2014;121(5):1045–1053. doi:10.1016/j.ophtha.2013.11.04124491642
   PubMed Web of Science ®Google Scholar
• Wells JA, Glassman AR, Ayala AR, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology. 2016;123(6):1351–1359. doi:10.1016/j.ophtha.2016.02.02226935357
   PubMed Web of Science ®Google Scholar
• Babiuch AS, Han M, Conti FF, Wai K, Silva FQ, Singh RP. Association of disorganization of retinal inner layers with visual acuity response to anti-vascular endothelial growth factor therapy for macular edema secondary to retinal vein occlusion. JAMA Ophthalmol. 2019;137(1):38–46. doi:10.1001/jamaophthalmol.2018.448430286219
   PubMed Web of Science ®Google Scholar
• Zhang M, Zhang J, Yan M, et al. A Phase 1 study of KH902, a vascular endothelial growth factor receptor decoy, for exudative age-related macular degeneration. Ophthalmology. 2011;118(4):672–678. doi:10.1016/j.ophtha.2010.08.00821146224
   PubMed Web of Science ®Google Scholar
• Do DV, Nguyen QD, Boyer D, et al. One-year outcomes of the da Vinci Study of VEGF Trap-Eye in eyes with diabetic macular edema. Ophthalmology. 2012;119(8):1658–1665. doi:10.1016/j.ophtha.2012.02.01022537617
   PubMed Web of Science ®Google Scholar
• Bressler SB, Qin H, Beck RW, et al. Factors associated with changes in visual acuity and central subfield thickness at 1 year after treatment for diabetic macular edema with ranibizumab. Arch Ophthalmol. 2012;130(9):1153–1161. doi:10.1001/archophthalmol.2012.110722965591
   PubMedGoogle Scholar
• Anderson DH, Mullins RF, Hageman GS, Johnson LV. A role for local inflammation in the formation of drusen in the aging eye. Am J Ophthalmol. 2002;134(3):411–431. doi:10.1016/S0002-9394(02)01624-012208254
   PubMed Web of Science ®Google Scholar
• Clermont AC, Cahill M, Salti H, et al. Hepatocyte growth factor induces retinal vascular permeability via MAP-kinase and PI-3 kinase without altering retinal hemodynamics. Invest Ophthalmol Vis Sci. 2006;47(6):2701–2708. doi:10.1167/iovs.05-007116723489
   PubMed Web of Science ®Google Scholar
• Klaassen I, Van Noorden CJ, Schlingemann RO. Molecular basis of the inner blood-retinal barrier and its breakdown in diabetic macular edema and other pathological conditions. Prog Retin Eye Res. 2013;34:19–48. doi:10.1016/j.preteyeres.2013.02.00123416119
   PubMed Web of Science ®Google Scholar
• Vujosevic S, Simo R. Local and systemic inflammatory biomarkers of diabetic retinopathy: an integrative approach. Invest Ophthalmol Vis Sci. 2017;58(6):BIO68–BIO75. doi:10.1167/iovs.17-2176928510630
   PubMed Web of Science ®Google Scholar
• Joussen AM, Poulaki V, Le ML, et al. A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J. 2004;18(12):1450–1452. doi:10.1096/fj.03-1476fje15231732
   PubMed Web of Science ®Google Scholar
• Jonas JB, Jonas RA, Neumaier M, Findeisen P. Cytokine concentration in aqueous humor of eyes with diabetic macular edema. Retina. 2012;32(10):2150–2157. doi:10.1097/IAE.0b013e3182576d0722617833
   PubMed Web of Science ®Google Scholar
• Lim SW, Bandala-Sanchez E, Kolic M, et al. The influence of intravitreal ranibizumab on inflammation-associated cytokine concentrations in eyes with diabetic macular edema. Invest Ophthalmol Vis Sci. 2018;59(13):5382–5390. doi:10.1167/iovs.17-2332530452591
   PubMed Web of Science ®Google Scholar
• Shimura M, Yasuda K, Motohashi R, Kotake O, Noma H. Aqueous cytokine and growth factor levels indicate response to ranibizumab for diabetic macular oedema. Br J Ophthalmol. 2017;101(11):1518–1523. doi:10.1136/bjophthalmol-2016-30995328270488
   PubMed Web of Science ®Google Scholar
• Figueras-Roca M, Sala-Puigdollers A, Zarranz-Ventura J, et al. Anatomic response to intravitreal dexamethasone implant and baseline aqueous humor cytokine levels in diabetic macular edema. Invest Ophthalmol Vis Sci. 2019;60(5):1336–1343. doi:10.1167/iovs.18-2621530933261
   PubMed Web of Science ®Google Scholar
• Lee WJ, Kang MH, Seong M, Cho HY. Comparison of aqueous concentrations of angiogenic and inflammatory cytokines in diabetic macular oedema and macular oedema due to branch retinal vein occlusion. Br J Ophthalmol. 2012;96(11):1426–1430. doi:10.1136/bjophthalmol-2012-30191322930681
   PubMed Web of Science ®Google Scholar
• Remick DG. Interleukin-8. Crit Care Med. 2005;33(12 Suppl):S466–S467. doi:10.1097/01.CCM.0000186783.34908.1816340423
   PubMed Web of Science ®Google Scholar
• Baggiolini M. Chemokines in pathology and medicine. J Intern Med. 2001;250(2):91–104. doi:10.1046/j.1365-2796.2001.00867.x11489059
   PubMed Web of Science ®Google Scholar
• Becher B, Tugues S, Greter M. GM-CSF: from growth factor to central mediator of tissue inflammation. Immunity. 2016;45(5):963–973. doi:10.1016/j.immuni.2016.10.02627851925
   PubMed Web of Science ®Google Scholar
• Gangur V, Simons FE, Hayglass KT. Human IP-10 selectively promotes dominance of polyclonally activated and environmental antigen-driven IFN-gamma over IL-4 responses. FASEB J. 1998;12(9):705–713. doi:10.1096/fasebj.12.9.7059619449
   PubMed Web of Science ®Google Scholar
• Azzurri A, Sow OY, Amedei A, et al. IFN-gamma-inducible protein 10 and pentraxin 3 plasma levels are tools for monitoring inflammation and disease activity in Mycobacterium tuberculosis infection. Microbes Infect. 2005;7(1):1–8. doi:10.1016/j.micinf.2004.09.00415716076
   PubMed Web of Science ®Google Scholar
• Schober A, Zernecke A. Chemokines in vascular remodeling. Thromb Haemost. 2007;97(5):730–737. doi:10.1160/TH07-02-008517479183
   PubMed Web of Science ®Google Scholar
• Mitchell P, Bandello F, Schmidt-Erfurth U, et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011;118(4):615–625. doi:10.1016/j.ophtha.2011.01.03121459215
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for diabetic macular edema: results from 2 Phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119(4):789–801. doi:10.1016/j.ophtha.2011.12.03922330964
   PubMed Web of Science ®Google Scholar
• Korobelnik JF, Do DV, Schmidt-Erfurth U, et al. Intravitreal aflibercept for diabetic macular edema. Ophthalmology. 2014;121(11):2247–2254. doi:10.1016/j.ophtha.2014.05.00625012934
   PubMed Web of Science ®Google Scholar
• Diabetic Retinopathy Clinical Research N, Elman MJ, Aiello LP, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010;117(6):1064–1077 e1035. doi:10.1016/j.ophtha.2010.02.03120427088
   PubMed Web of Science ®Google Scholar
• Ishibashi T, Li X, Koh A, et al. The REVEAL study: ranibizumab monotherapy or combined with laser versus laser monotherapy in Asian patients with diabetic macular edema. Ophthalmology. 2015;122(7):1402–1415. doi:10.1016/j.ophtha.2015.02.00625983216
   PubMed Web of Science ®Google Scholar
• Mitchell P, Wong TY. Diabetic macular edema treatment guideline working G. Management paradigms for diabetic macular edema. Am J Ophthalmol. 2014;157(3):505-513e501-508. doi:10.1016/j.ajo.2013.11.012
   Web of Science ®Google Scholar
• Noma H, Mimura T, Yasuda K, Motohashi R, Kotake O, Shimura M. Aqueous humor levels of soluble vascular endothelial growth factor receptor and inflammatory factors in diabetic macular edema. Ophthalmologica. 2017;238(1–2):81–88. doi:10.1159/00047560328564655
   PubMed Web of Science ®Google Scholar
• Sun Z, Zhou H, Lin B, et al. Efficacy and safety of intravitreal conbercept injections in macular edema secondary to retinal vein occlusion. Retina. 2017;37(9):1723–1730. doi:10.1097/IAE.000000000000140427893623
   PubMed Web of Science ®Google Scholar
• Li F, Zhang L, Wang Y, et al. One-year outcome of conbercept therapy for diabetic macular edema. Curr Eye Res. 2018;43(2):218–223. doi:10.1080/02713683.2017.137954229265939
   PubMed Web of Science ®Google Scholar
• Roh MI, Kim HS, Song JH, Lim JB, Kwon OW. Effect of intravitreal bevacizumab injection on aqueous humor cytokine levels in clinically significant macular edema. Ophthalmology. 2009;116(1):80–86. doi:10.1016/j.ophtha.2008.09.03619118699
   PubMed Web of Science ®Google Scholar
• Funk M, Schmidinger G, Maar N, et al. Angiogenic and inflammatory markers in the intraocular fluid of eyes with diabetic macular edema and influence of therapy with bevacizumab. Retina. 2010;30(9):1412–1419. doi:10.1097/IAE.0b013e3181e095c020711086
   PubMed Web of Science ®Google Scholar
• Sohn HJ, Han DH, Kim IT, et al. Changes in aqueous concentrations of various cytokines after intravitreal triamcinolone versus bevacizumab for diabetic macular edema. Am J Ophthalmol. 2011;152(4):686–694. doi:10.1016/j.ajo.2011.03.03321782151
   PubMed Web of Science ®Google Scholar
• Wen J, Jiang Y, Zheng X, Zhou Y. Six-month changes in cytokine levels after intravitreal bevacizumab injection for diabetic macular oedema and macular oedema due to central retinal vein occlusion. Br J Ophthalmol. 2015;99(10):1334–1340. doi:10.1136/bjophthalmol-2014-30634125841235
   PubMed Web of Science ®Google Scholar
• Agrawal R, Balne PK, Wei X, et al. Cytokine profiling in patients with exudative age-related macular degeneration and polypoidal choroidal vasculopathy. Invest Ophthalmol Vis Sci. 2019;60(1):376–382. doi:10.1167/iovs.18-2438730682207
   PubMed Web of Science ®Google Scholar
• Ghodasra DH, Fante R, Gardner TW, et al. Safety and feasibility of quantitative multiplexed cytokine analysis from office-based vitreous aspiration. Invest Ophthalmol Vis Sci. 2016;57(7):3017–3023. doi:10.1167/iovs.15-1872127273720
   PubMed Web of Science ®Google Scholar
• Campochiaro PA, Hafiz G, Mir TA, et al. Pro-permeability factors in diabetic macular edema; the diabetic macular edema treated with ozurdex trial. Am J Ophthalmol. 2016;168:13–23. doi:10.1016/j.ajo.2016.04.01727130369
   PubMed Web of Science ®Google Scholar
• Hillier RJ, Ojaimi E, Wong DT, et al. aqueous humor cytokine levels and anatomic response to intravitreal ranibizumab in diabetic macular edema. JAMA Ophthalmol. 2018;136(4):382–388. doi:10.1001/jamaophthalmol.2018.017929522144
   PubMed Web of Science ®Google Scholar